Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Introduction: Down syndrome (DS) is associated with an almost universal development of Alzheimer's disease. Individuals with DS are therefore an important population for randomized controlled trials to prevent or delay cognitive decline, though it is essential to understand the time course of early cognitive changes. Methods: We conducted the largest cognitive study to date with 312 adults with DS to assess age‐related and Alzheimer's disease–related cognitive changes during progression from preclinical to prodromal dementia, and prodromal to clinical dementia. Results: Changes in memory and attention measures were most sensitive to early decline. Resulting sample size calculations for randomized controlled trials to detect significant treatment effects to delay decline were modest. Discussion: Our findings address uncertainties around the development of randomized controlled trials to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in people with DS and could serve as proof‐of‐principle trials for some drug targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific impairments of planning
Shallice, T. (1982) · Philosophical Transactions of the Royal Society of London. B, Biological Sciences · doi:10.1098/rstb.1982.0082 · Cited by 3,741
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925 · cited 2×
“[25], defining preclinical dementia by the absence of clinical symptoms of AD and the presence of AD biomarker changes.”
BackgroundA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“The recent failure of clinical drug trials directed at amyloid, including anti-amyloid antibodies and BACE inhibition, has been a considerable disappointment given the genetic evidence suggesting reduced BACE cleavage over a lifetime protects against AD [42].”
BackgroundBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562 · cited 5×
“Owing to postmortem studies indicating amyloid neuropathology in DS by the mid-30s [2,4], we considered those aged 361 years with no clinical symptoms of dementia to be in a preclinical state, and those with cognitive symptoms but no clinical diagnosis of dementia in a prodromal state.”
BackgroundInfluentialSelf-citationBehavior Rating Inventory of Executive Function®--Adult Version
Roth, R. M., Isquith, P. K., & Gioia, G. A. (2022) · PsycTESTS Dataset · doi:10.1037/t86244-000 · Cited by 323
Outcome Measures for Clinical Trials in Down Syndrome
Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d'Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.247 · Cited by 153 · cited 1×
“RCTs would likely use several outcomes, both assessed directly and via informant report (with the latter particularly important for those with more severe ID [44]), and our results offer a critical first step toward such trials.”
Cited by
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Self-citationAlzheimer's disease associated with Down syndrome: a genetic form of dementia
Fortea, J., Zaman, S. H., Hartley, S., Rafii, M. S., Head, E., & Carmona-Iragui, M. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00245-3 · Cited by 357
Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome
Iulita, M. F., Garzón Chavez, D., Klitgaard Christensen, M., Valle Tamayo, N., Plana-Ripoll, O., Rasmussen, S. A., Roqué Figuls, M., Alcolea, D., Videla, L., Barroeta, I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.12910 · Cited by 195
Alić, I., Goh, P. A., Murray, A., Portelius, E., Gkanatsiou, E., Gough, G., Mok, K. Y., Koschut, D., Brunmeir, R., Yeap, Y. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0806-5 · Cited by 123
Self-citationCharacterizing the emergence of amyloid and tau burden in Down syndrome
Zammit, M. D., Betthauser, T. J., McVea, A. K., Laymon, C. M., Tudorascu, D. L., Johnson, S. C., Hartley, S. L., Converse, A. K., Minhas, D. S., Zaman, S. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13444 · Cited by 60
“Measuring cognitive decline in individuals with DS can also be challenging due to their lower and varied baseline intellectual functioning level compared to neurotypical populations, 55–57 adding further uncertainty to age-based EYO classification.”
Background
Metadata
- Authors
- Startin, C. M., Hamburg, S., Hithersay, R., Al‐Janabi, T., Mok, K. Y., Hardy, J., LonDownS Consortium, & Strydom, A.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2018-11-28
- Volume
- 15
- Issue
- 2
- Pages
- 245-257
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2902067283
- Cited by
- 97
- References
- 7
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. https://app.cochat.ai/papers/10.1016/j.jalz.2018.08.009
- The paper
- Startin, C. M., Hamburg, S., Hithersay, R., Al‐Janabi, T., Mok, K. Y., Hardy, J., LonDownS Consortium, & Strydom, A. (2019). Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2018.08.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.